HMG B.P.

BSV Bioscience GmbH provides a wide range of biological pharmaceutical active ingredients which includes HMG B.P. It is a combination of the two pituitary gonadotrophic hormones “follicle stimulating hormone” (FSH) and “luteinizing hormone” (LH). The proportion of these two hormones in menotrophin is approximately 1:1. These hormones are secreted by pituitary glands together with the thyroid stimulating hormone (TSH). Menotrophin (HMG) supports the normal development of an egg in a woman's ovary and stimulates the release of the egg during ovulation. In the male, it stimulates the spermatogenesis by acting on the production of the androgen-binding protein in the seminiferous tubules of the sertoli cells. Structure: consist of two non-identical subunits: the alpha subunit and the beta subunit. The molecular weight of each of these glycoprotein hormones is ca. 32,000 Dalton, with each subunit having a molecular weight of ca. 16,000 Dalton. The structure of FSH and LH is similar to the structure of the Thyroid Stimulating Hormone (TSH) and human chorionic gonadotrophin (HCG). The alpha subunits of FSH, LH, TSH and HCG are identical and consist of 92 amino acids. Therapeutic indication: it is used to stimulate the development of multiple oocytes in ovulatory patients participating in an in vivo fertility program. Further it is given to assist in the intrauterine insemination (IUI) treatment and in vitro fertilization technique (IVF). it indicated in Hypogonadotrophic hypopituitarism (WHO group I patients) where both gonadotropin stimulations are needed. In patients showing normal or high LH levels (WHO group II patients), require preparations without LH activity, this character belongs to FSH (follicle stimulating hormone).